Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733260 | 0.87 | TRPV1 (0.39) | SCDSCD5MAPTTRPV1RORC | |
| SCHEMBL31050097 | 0.85 | MAPT (0.37) | SCDSCD5MAPTTRPV1RORC | |
| SCHEMBL30186170 | 0.85 | MAPT (0.37) | SCDSCD5MAPTTRPV1RORC | |
| SCHEMBL23064279 | 0.85 | MAPT (0.37) | SCDSCD5MAPTTRPV1RORC | |
| SCHEMBL23064280 | 0.85 | MAPT (0.37) | SCDSCD5MAPTTRPV1RORC | |
| SCHEMBL23064379 | 0.85 | MAPT (0.37) | SCDSCD5MAPTTRPV1RORC | |
| SCHEMBL23283038 | 0.79 | TRPV1 (0.39) | SCDSCD5MAPTTRPV1EPHX2 | |
| SCHEMBL23064245 | 0.74 | ALDH1A1 (0.48) | SCDSCD5MAPTL3MBTL1CNR1 | |
| SCHEMBL3325476 | 0.73 | MAPT (0.50) | MAPTTRPV1L3MBTL1JAK1 | |
| SCHEMBL28895282 | 0.71 | TRPV1 (0.43) | SCDSCD5MAPTTRPV1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | SCD 4229/4885SCD5 4333/4885MAPT 4874/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | SCD 4229/4885SCD5 4333/4885MAPT 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.